DGX Relative Valuation
DGX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, DGX is overvalued; if below, it's undervalued.
Historical Valuation
Quest Diagnostics Inc (DGX) is now in the Overvalued zone, suggesting that its current forward PE ratio of 17.92 is considered Overvalued compared with the five-year average of 14.84. The fair price of Quest Diagnostics Inc (DGX) is between 130.50 to 169.01 according to relative valuation methord. Compared to the current price of 173.97 USD , Quest Diagnostics Inc is Overvalued By 2.93%.
Relative Value
Fair Zone
130.50-169.01
Current Price：173.97
2.93%
Overvalued
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
2.86
P/B
Median3y
2.51
Median5y
2.57
5.35
FCF Yield
Median3y
6.36
Median5y
7.81
Competitors Valuation Multiple
The average P/S ratio for DGX's competitors is 1.37, providing a benchmark for relative valuation. Quest Diagnostics Inc Corp (DGX) exhibits a P/S ratio of 1.81, which is 31.61% above the industry average. Given its robust revenue growth of 12.09%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is Quest Diagnostics Inc (DGX) currently overvalued or undervalued?
What is Quest Diagnostics Inc (DGX) fair value?
How does DGX's valuation metrics compare to the industry average?
What is the current P/B ratio for Quest Diagnostics Inc (DGX) as of Jul 08 2025?
What is the current FCF Yield for Quest Diagnostics Inc (DGX) as of Jul 08 2025?
What is the current Forward P/E ratio for Quest Diagnostics Inc (DGX) as of Jul 08 2025?